Department of Respiratory and Critical Care Medicine, Xiamen Haicang Hospital, Xiamen, China.
Department of Respiratory Section II, The Third Hospital of Xiamen Affiliated to Fujian University of Traditional Chinese Medicine, Xiamen, China.
Sci Rep. 2022 Feb 11;12(1):2389. doi: 10.1038/s41598-022-06378-2.
Cardiac damage in non-severe patients with coronavirus disease 2019 (COVID-19) is poorly explored. This study aimed to explore the manifestations of cardiac damage at presentation in non-severe patients with COVID-19. In this study, 113 non-severe patients with COVID-19 were grouped according to the duration from symptoms onset to hospital admission: group 1 (≤ 1 week, n = 27), group 2 (> 1 to 2 weeks, n = 28), group 3 (> 2 to 3 weeks, n = 27), group 4 (> 3 weeks, n = 31). Clinical, cardiovascular, and radiological data on hospital admission were compared across the four groups. The level of high sensitivity troponin I (hs-cTnI) in group 2 [10.25 (IQR 6.75-15.63) ng/L] was significantly higher than those in group 1 [1.90 (IQR 1.90-8.80) ng/L] and group 4 [1.90 (IQR 1.90-5.80) ng/L] (all P < 0.05). The proportion of patients who had a level of hs-cTnI ≥ 5 ng/L in group 2 (85.71%) was significantly higher than those in the other three groups (37.04%, 51.85%, and 25.81%, respectively) (all P < 0.05). Compared with patients with hs-cTnI under 5 ng/L, those with hs-cTnI ≥ 5 ng/L had lower lymphocyte count (P = 0.000) and SpO (P = 0.002) and higher CRP (P = 0.000). Patients with hs-cTnI ≥ 5 ng/L had a higher incidence of bilateral pneumonia (P = 0.000) and longer hospital length of stay (P = 0.000). In conclusion, non-severe patients with COVID-19 in the second week after symptoms onset were most likely to suffer cardiac damage. A detectable level of hs-cTnI ≥ 5 ng/L might be a manifestation of early cardiac damage in the patients.
在患有 2019 年冠状病毒病（COVID-19）的非重症患者中心脏损伤的研究仍较少。本研究旨在探讨非重症 COVID-19 患者入院时心脏损伤的表现。本研究根据症状出现至入院的时间将 113 例非重症 COVID-19 患者分为 4 组：第 1 组（≤1 周，n=27），第 2 组（>1 至 2 周，n=28），第 3 组（>2 至 3 周，n=27），第 4 组（>3 周，n=31）。比较 4 组患者入院时的临床、心血管和影像学数据。第 2 组[10.25（IQR 6.75-15.63）ng/L]高敏肌钙蛋白 I（hs-cTnI）水平显著高于第 1 组[1.90（IQR 1.90-8.80）ng/L]和第 4 组[1.90（IQR 1.90-5.80）ng/L]（均 P<0.05）。第 2 组 hs-cTnI≥5ng/L 的患者比例（85.71%）明显高于其他 3 组（分别为 37.04%、51.85%和 25.81%）（均 P<0.05）。与 hs-cTnI<5ng/L 的患者相比，hs-cTnI≥5ng/L 的患者淋巴细胞计数较低（P=0.000），SpO 较低（P=0.002），CRP 较高（P=0.000）。hs-cTnI≥5ng/L 的患者双侧肺炎发生率较高（P=0.000），住院时间较长（P=0.000）。总之，症状出现后第 2 周的非重症 COVID-19 患者最有可能发生心脏损伤。hs-cTnI 检测水平≥5ng/L 可能是患者早期心脏损伤的表现。
